Rational Pharmacotherapy for Tinnitus - Recent Advances and Perspectives

    Corporate Symposium at the Annual Meeting of the American Association of Otolaryngology - Head and Neck Surgery Foundation
    Orlando, September 23, 2014

    Symposium Chair: Hinrich Staecker, MD, PhD.

    Copyright by the authors

    Pathophysiology of tinnitus

    What do we know about pharmacologic targets for tinnitus treatments?
    Richard Salvi, PhD, University at Buffalo, Hearing Research Lab, Buffalo NY

    Glutamate excitotoxicity and tinnitus
    Marlies Knipper, PhD, Tübingen Hearing Research Center, Molecular Physiology of Hearing, Tübingen, Germany

    Efficacy outcomes in clinical tinnitus research

    Use of patient reported outcomes in tinnitus research
    Carla deMuro, MS, Head Patient Reported Outcomes, RTI Health Solutions,
    Research Triangle Park NC

    Development and clinical use of the Tinnitus Functional Index
    James Henry, PhD, National Center for Rehabilitative Auditory Research,
    VA Medical Center, Portland OR

    Intratympanic injections for tinnitus therapy

    Safety of intratympanic injections
    Lyon Gleich, MD, Vice President Medical Affairs, Medpace, Inc., Cincinnati OH

    Best practice for intratympanic injections – roundtable discussion
    Moderator: Lyon Gleich, MD

    Developments in clinical tinnitus research

    Clinical use of NMDA receptor antagonists for tinnitus therapy
    Hinrich Staecker, MD, PhD, Department of Otolaryngology Head and Neck
    Surgery, University of Kansas Medical Center, Kansas City KS